कंपनी का अवलोकन
AC Immune SA operates as a clinical-stage biopharmaceutical entity dedicated to the discovery, design, and development of therapeutic and diagnostic products aimed at preventing and treating neurodegenerative diseases caused by protein misfolding. The company functions within the Healthcare sector and specifically the Biotechnology industry, an environment characterized by high-risk research and development cycles where capital allocation is critical for advancing scientific breakthroughs into marketable medicines. As of the latest reporting period, the company maintains a market capitalization of $346.03M and employs a workforce of 90 individuals to support its specialized research initiatives. These financial metrics, particularly the market cap relative to its annual revenue of $3.57M, indicate that the company is valued significantly above its current sales base, a common characteristic for pre-commercial biotechnology firms where valuation is derived from the potential of future intellectual property and pipeline assets rather than established cash flows.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $3.57M, yet it simultaneously recorded a net income of $-70,447,000 and an EBITDA of $-67,470,000, revealing a substantial gap between top-line sales and bottom-line profitability driven by heavy research and development expenditures. This negative earnings position results in a free cash flow of $-41,761,752, which signifies a continuous consumption of cash reserves required to sustain operations and fund clinical trials without external financing. The margin profile shows a Gross Margin of 0.0%, an Operating Margin of -4262.1%, and a Profit Margin of 0.0%, indicating that current revenue does not cover variable production costs or operational expenses sufficient to generate a positive spread. Despite the operational losses, the company holds cash assets totaling $91.41M against a debt obligation of $4.54M, resulting in a Debt to Equity ratio of 10.12 which suggests a highly leveraged balance sheet relative to equity, though the absolute debt level is manageable given the cash on hand. Liquidity is assessed via a Current Ratio of 1.02, indicating that current assets barely exceed current liabilities, which reflects a tight short-term liquidity position typical for cash-burning biotech firms. Furthermore, the Return on Equity stands at -89.7% and the Return on Assets at -22.3%, metrics that reveal that management is currently generating negative returns on the capital invested, a standard phase for companies in the early stages of drug development before commercialization milestones are reached.
मूल्यांकन आकलन
Valuation metrics for AC Immune SA include a Trailing P/E Ratio of N/A due to negative earnings, while the Forward P/E is listed at 5.55, implying that the market is pricing in expected future profitability that does not yet reflect in current trailing figures. The Price to Book ratio stands at 6.15, suggesting that the market values the company at more than six times its net asset value, a premium often associated with intangible assets like patents and proprietary platforms that are not fully captured on the balance sheet. Alternative valuation measures such as a Price to Sales ratio of 96.85 and an EV/EBITDA of -3.71 further illustrate the disconnect between current sales and enterprise value, highlighting that the stock price is largely decoupled from current operational performance. Regarding trading range, the 52-Week High is $4.00 and the 52-Week Low is $1.43; if the current price is assumed to be near the low end based on recent trading patterns, the stock trades significantly below its 52-week high, reflecting market sentiment regarding the high risk of the underlying asset. The Beta of 1.63 indicates that the stock price exhibits 63% higher volatility than the broader market, meaning that price movements are amplified by general market fluctuations, a characteristic feature of small-cap biotechnology equities.
Growth & Income
The company experienced a Revenue Growth of -70.3% year-over-year, while Earnings Growth is listed as N/A due to the absence of positive earnings in the prior period, indicating that the business is contracting in terms of sales rather than expanding. Since the company does not pay a dividend, with a Dividend Yield of N/A and a Payout Ratio of 0.0%, all available cash flow is necessarily reinvested into R&D and operational continuity rather than distributed to shareholders. The negative revenue growth combined with negative earnings growth underscores the challenges of transitioning from research phases to commercial sales, where the company must expand its revenue base to achieve profitability. Consequently, the overall growth and income profile for AC Immune SA is defined by significant contraction in sales and a complete reliance on retained cash reserves to fund future development, with no current income generation mechanism in place for investors.